Selective binding agents of interferon-gamma (IFN.gamma.) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to IFN.gamma. and may be used to prevent or treat conditions relating to autoimmune and inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis. Nucleic acid molecules encoding said antibodies and antigen binding domains, and expression vectors and host cells for the production of same are also provided.